ProQR
ProQR Therapeutics NV (NASDAQ: PRQR) is a Dutch biotechnology company based in Leiden, the Netherlands. ProQR was founded in 2012 by CEO Daniel de Boer and co-founders Henri Termeer,[1][2][3] Dinko Valerio[3][4] and Gerard Platenburg.[3][4] The company’s current pipeline includes potential treatments for rare genetic diseases[5] including Leber's congenital amaurosis, (LCA10)[5][6] dystrophic epidermolysis bullosa[5][6] and Usher syndrome.[7]
Type | Public |
---|---|
NASDAQ: PRQR | |
Industry | Biotechnology Pharmaceuticals |
Founded | 2012 |
Headquarters | LEIDEN |
Key people | Daniel de Boer (CEO) |
Products | Developing transformative RNA medicines |
Number of employees |
|
Website | http://www.proqr.com/ |
ProQR is targeting genetic diseases by focusing on making changes to the RNA.[8] The firm's RNA editing technology, called Axiomer[7], can make targeted single nucleotide changes to RNA.
One of the company’s lead candidates,[9] QR-110, is being developed to treat LCA10.[10] The substance acts by binding the mutated section of the RNA which will allow a formation of a normal CEP290 protein.[11]
References
- Weisman, Robert (January 20, 2018). "Henri Termeer isn't exactly settling into retirement". The Boston Globe.
- McBride, Ryan (May 10, 2013). "Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups". FierceBiotech.
- Carroll, John (Sep 9, 2014). "Termeer-backed ProQR lays out terms for $75M IPO". FierceBiotech.
- Taylor, Nick Paul (Sep 13, 2017). "ProQR spins out CNS assets to form RNA rare disease biotech". FierceBiotech.
- Rodríguez Fernández, Clara (March 12, 2018). "A Dutch Company on the Quest Against Cystic Fibrosis". LaBiotech.eu.
- Rossi, Krista (May 25, 2018). "Daniel de Boer, CEO of ProQR, Explains RNA Treatment, QR-313, for DEB". Rare Disease Report.
- Dale, Alex (Feb 13, 2018). "ProQR Tackles Blindness Caused by a Rare". LaBiotech.eu.
- "The Art of Editing RNA". Research & Development. 2017-09-22. Retrieved 2018-10-04.
- Mathias, Tamara. "ProQR soars as childhood blindness drug succeeds in early trial". U.S. Retrieved 2018-10-04.
- Kilgore, Tomi. "ProQR's stock rockets to pace all gainers after upbeat drug trial results". MarketWatch. Retrieved 2018-10-04.
- "Proqr hits the gas on blindness project". Evaluate.com. Retrieved 2018-10-04.